The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of mirabegron, having considered evidence on the nature of overactive bladder (OAB) and the value placed on ...

TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved ...

G_older_woman_urinary_incontinence Phase 4 trial showed that mirabegron significantly decreased incontinence episodes and micturitions compared with placebo among patients aged 65 years and older.

Mirabegron has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...

Review the side-effects of Mirabegron as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization. The Food and Drug Administration ...

TOKYO, June 29, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the submission of a supplemental New Drug Application (sNDA) to ...

Please provide your email address to receive an email when new articles are posted on . Sofosbuvir, mirabegron and nintedanib — all approved within the past 9 years — are among the drugs associated ...

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the ...

Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable ...